Delivering extraordinary. Empowering ordinary.

We’re developing novel oral medicines for rare diseases to help patients take part in the everyday activities they enjoy.

Learn More

Structure-guided Drug Design

We combine traditional cell biology with medicinal chemistry to build synthetic compounds that bind to specific protein targets to fight disease.

See Our Science

We are developing a pipeline of oral drugs for rare diseases.

View Our Pipeline

Stay up to date with the latest discoveries, events, and reports from BioCryst.

June 22, 2022: BioCryst Announces ORLADEYO® (berotralstat) Data to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2022
June 9, 2022: BioCryst Selects Pint Pharma as Commercial Partner for ORLADEYO® (berotralstat) in Latin America
June 8, 2022: FDA Grants Fast Track Designation for BioCryst’s ALK-2 Inhibitor, BCX9250

VIEW ALL PRESS RELEASES

We are a collection of passionate individuals united by a commitment to scientific excellence and an unwavering focus on the needs of patients.

JOB OPENINGS